Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Osteoporosis

  Free Subscription


12.08.2019

1 J Clin Endocrinol Metab
3 Osteoporos Int
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    J Clin Endocrinol Metab

  1. MAJOOR BCJ, Papapoulos SE, Dijkstra PDS, Fiocco M, et al
    Denosumab in Patients with Fibrous Dysplasia Previously Treated with Bisphosphonates.
    J Clin Endocrinol Metab. 2019 Aug 7. pii: 5544499. doi: 10.1210/jc.2018-02543.
    PubMed     Text format     Abstract available


    Osteoporos Int

  2. SUGIMOTO T, Shiraki M, Fukunaga M, Kishimoto H, et al
    Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study.
    Osteoporos Int. 2019 Aug 8. pii: 10.1007/s00198-019-05111.
    PubMed     Text format     Abstract available

  3. HILIGSMANN M, Cornelissen D, Vrijens B, Abrahamsen B, et al
    Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskel
    Osteoporos Int. 2019 Aug 7. pii: 10.1007/s00198-019-05104.
    PubMed     Text format     Abstract available

  4. HARRIS AM, Lee AR, Wong SC
    Systematic review of the effects of bisphosphonates on bone density and fracture incidence in childhood acute lymphoblastic leukaemia.
    Osteoporos Int. 2019 Aug 3. pii: 10.1007/s00198-019-05082.
    PubMed     Text format     Abstract available


    PLoS One

  5. YEH PS, Lee YW, Chang WH, Wang W, et al
    Biomechanical and tomographic differences in the microarchitecture and strength of trabecular and cortical bone in the early stage of male osteoporosis.
    PLoS One. 2019;14:e0219718.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Osteoporosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: